<DOC>
	<DOCNO>NCT02382510</DOCNO>
	<brief_summary>This multiple ascend dose study determine safety bronchodilator activity TRN-157 59 mild moderate asthmatic .</brief_summary>
	<brief_title>Multiple Ascending Dose Study TRN-157 Stable Mild Moderate Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Patients meet follow criterion consider eligible participate study : The patient ≥ 18 &lt; 70 year age , give informed consent Clinical diagnosis mild moderate asthma least 6 month duration age onset &lt; 50 year Presently use ICS moderate dos ( equivalent 200800 µg budesonide 88500 µg fluticasone daily ) ≥ 12 % ≥ 200 mL improvement FEV1 4 puff albuterol metereddose inhaler ( MDI ) screen visit Patient willing use acceptable form birth control trial one month thereafter Ability measure morning ( AM ) peak expiratory flow ( PEF ) schedule use electronic peak flow meter ( EPFM ) complete study diary correctly least 70 % time runin period After 7 day withdrawal LABA therapy overnight withdrawal SABA therapy ( except rescue medication ) , patient 55 % 80 % predict FEV1 CV2 A patient meeting follow criterion eligible enrollment study : A clinical diagnosis chronic obstructive pulmonary disease ( COPD ) , chronic bronchitis , bronchiectasis , significant pulmonary disease asthma History upper low respiratory infection within 4 week screen History asthma exacerbation require oral systemic corticosteroid hospital admission within 6 month screen History myocardial infarction , cardiac conduction abnormality , include limited atrial fibrillation , paroxysmal atrial tachycardia Hospitalization due cardiac failure within last 6 month History narrow angle glaucoma obstructive uropathy Current smoker vapers , former smoker &gt; 10 packyear ( selfreported ) history smoke Patients presently use follow medication eligible participation : Longacting muscarinic receptor antagonist ( LAMA ) LABA ( may withdraw convert SABA x 7 day prior entry ) Leukotriene pathway blocker AntiIgE antibody ( Xolair ) within last 6 month prior CV1 Phosphodiesterase 4 ( PDE4 ) inhibitor ( e.g. , Roflumilast ) Cromolyn Methylxanthines ( e.g. , aminophylline theophylline ) 5Lipoxygenase inhibitor ( e.g. , Zileuton ) Allergies LAMA therapy History lifethreatening asthma exacerbation require ICU admission , mechanical ventilation , tracheostomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>